Paper180200
Effect of human exogenous leukocyte interferon in cytomegalovirus infections.
Emödi G and 5 others. J Infect Dis, 1976. Cited by 47 papers, by iCite.
Cite this record
ConductScience Library. Effect of human exogenous leukocyte interferon in cytomegalovirus infections. Papers, record 180200. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/180200
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytomegalovirus Infections | Major topic |
| Interferons | Major topic |
| Adult | |
| Cytomegalovirus | |
| Female | |
| Humans | |
| Infant | |
| Infant, Newborn | |
| Infant, Newborn, Diseases | |
| Infant, Premature, Diseases | |
| Lectins | |
| Lymphocytes | |
| Male | |
| Virus Diseases |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38063292 | Inhibition of human cytomegalovirus replication by interferon alpha can involve multiple anti-viral factors. | J Gen Virol | 2023 | https://conductscience.org/library/papers/38063292 | PubMed |
| 30449131 | Cyclophilin A as a target in the treatment of cytomegalovirus infections. | Antivir Chem Chemother | 2018 | https://conductscience.org/library/papers/30449131 | PubMed |
| 30403913 | Human monocyte-derived macrophages inhibit HCMV spread independent of classical antiviral cytokines. | Virulence | 2018 | https://conductscience.org/library/papers/30403913 | PubMed |
| 29194430 | Human Cytomegalovirus Encoded miR-US25-1-5p Attenuates CD147/EMMPRIN-Mediated Early Antiviral Response. | Viruses | 2017 | https://conductscience.org/library/papers/29194430 | PubMed |
| 29021395 | Human Cytomegalovirus Utilizes a Nontraditional Signal Transducer and Activator of Transcription 1 Activation Cascade via Signaling through Epidermal Growth Factor Receptor and Integrins To Efficiently Promote the Motility, Differentiation, and Polarization of Infected Monocytes. | J Virol | 2017 | https://conductscience.org/library/papers/29021395 | PubMed |
| 25392213 | Abrogation of the interferon response promotes more efficient human cytomegalovirus replication. | J Virol | 2015 | https://conductscience.org/library/papers/25392213 | PubMed |
| 24013068 | The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus. | J Mol Biol | 2013 | https://conductscience.org/library/papers/24013068 | PubMed |
| 6208021 | Interferons and viral infections. | Eur J Clin Microbiol | 1984 | https://conductscience.org/library/papers/6208021 | PubMed |
| 6173188 | Interferons and interferon inducers: development of clinical usefulness and therapeutic promise. | Drugs | 1982 | https://conductscience.org/library/papers/6173188 | PubMed |
| 6163727 | Protective effect of low-dose interferon against neonatal murine cytomegalovirus infection. | Infect Immun | 1981 | https://conductscience.org/library/papers/6163727 | PubMed |
| 6163417 | Interferon therapy: pharmacokinetic and pharmacological aspects. | Arch Virol | 1981 | https://conductscience.org/library/papers/6163417 | PubMed |
| 6159043 | Interferon: therapeutic fact or fiction for the '80s? | Br Med J | 1980 | https://conductscience.org/library/papers/6159043 | PubMed |
| 500189 | Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. | Infect Immun | 1979 | https://conductscience.org/library/papers/500189 | PubMed |
| 318786 | Cell-mediated immunity and its role in resistance to infection. | West J Med | 1977 | https://conductscience.org/library/papers/318786 | PubMed |
| 229129 | Herpesviruses. | J Clin Pathol | 1979 | https://conductscience.org/library/papers/229129 | PubMed |
| 206203 | Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic-polycytidylic acid, and polyinosinic-polycytidylic acid-poly-L-lysine complex. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/206203 | PubMed |
| 193440 | Susceptibility of clinical isolates of cytomegalovirus to human interferon. | Antimicrob Agents Chemother | 1977 | https://conductscience.org/library/papers/193440 | PubMed |
| 186979 | [Experiments with simultaneous immunization against cytomegalovirus infection and rubella]. | Soz Praventivmed | 1976 | https://conductscience.org/library/papers/186979 | PubMed |
| 185951 | Effect of treatment with exogenous interferon, polyinosinic acid-polyctyidylic acid or polyinosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice. | Antimicrob Agents Chemother | 1976 | https://conductscience.org/library/papers/185951 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/180200
GET https://conductscience.org/api/papers/v1/180200/authors